JP7524899B2 - ベンゾトリアゾール誘導体 - Google Patents

ベンゾトリアゾール誘導体 Download PDF

Info

Publication number
JP7524899B2
JP7524899B2 JP2021522912A JP2021522912A JP7524899B2 JP 7524899 B2 JP7524899 B2 JP 7524899B2 JP 2021522912 A JP2021522912 A JP 2021522912A JP 2021522912 A JP2021522912 A JP 2021522912A JP 7524899 B2 JP7524899 B2 JP 7524899B2
Authority
JP
Japan
Prior art keywords
methyl
benzo
dimethyl
triazol
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522912A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020241853A5 (cg-RX-API-DMAC7.html
JPWO2020241853A1 (cg-RX-API-DMAC7.html
Inventor
健一 小森
勇人 西山
尚哉 木下
幸周 和田
晃佑 森下
明之 二宮
悠祐 白石
和弘 大沼
彩矢佳 小木
寛義 川田
富美夫 木村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Corp filed Critical Ube Corp
Publication of JPWO2020241853A1 publication Critical patent/JPWO2020241853A1/ja
Publication of JPWO2020241853A5 publication Critical patent/JPWO2020241853A5/ja
Application granted granted Critical
Publication of JP7524899B2 publication Critical patent/JP7524899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021522912A 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体 Active JP7524899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019102529 2019-05-31
JP2019102529 2019-05-31
PCT/JP2020/021426 WO2020241853A1 (ja) 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体

Publications (3)

Publication Number Publication Date
JPWO2020241853A1 JPWO2020241853A1 (cg-RX-API-DMAC7.html) 2020-12-03
JPWO2020241853A5 JPWO2020241853A5 (cg-RX-API-DMAC7.html) 2023-05-12
JP7524899B2 true JP7524899B2 (ja) 2024-07-30

Family

ID=73553193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522912A Active JP7524899B2 (ja) 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体

Country Status (11)

Country Link
US (1) US12559504B2 (cg-RX-API-DMAC7.html)
EP (1) EP3978073B1 (cg-RX-API-DMAC7.html)
JP (1) JP7524899B2 (cg-RX-API-DMAC7.html)
KR (1) KR102978107B1 (cg-RX-API-DMAC7.html)
CN (1) CN114174289B (cg-RX-API-DMAC7.html)
AU (1) AU2020283361B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023927A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142295A1 (cg-RX-API-DMAC7.html)
ES (1) ES3047102T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021014680A (cg-RX-API-DMAC7.html)
WO (1) WO2020241853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN113024399B (zh) * 2021-03-11 2022-09-09 华东理工大学 药物中间体化合物及其制备方法、应用
KR102994906B1 (ko) * 2022-01-14 2026-07-24 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조 방법
CA3256688A1 (en) * 2022-04-28 2025-04-22 Daiichi Sankyo Company, Limited BENZOTRIAZOLE COMPOUND
WO2023210740A1 (ja) * 2022-04-28 2023-11-02 第一三共株式会社 ベンゾチオフェン化合物
EP4696692A1 (en) * 2023-06-19 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
WO2025192605A1 (ja) * 2024-03-12 2025-09-18 株式会社GALTS Pharma 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202253A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2018109647A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
JP2021535118A (ja) 2018-08-20 2021-12-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1−Nrf2タンパク質−タンパク質相互作用の阻害剤
JP2022520442A (ja) 2019-02-15 2022-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784244T3 (es) 2013-12-18 2020-09-23 Glaxosmithkline Ip Dev Ltd Reguladores de Nrf2
WO2016013657A1 (ja) 2014-07-25 2016-01-28 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
KR20190088404A (ko) 2016-12-06 2019-07-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 3-(2,3-디히드로-1h-인덴-5-일)프로판산 유도체 및 nrf2 조절제로서의 그의 용도
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのエーテル結合トリアゾール
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
WO2019116230A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
US11643407B2 (en) 2018-05-23 2023-05-09 Glaxosmithkline Intellectual Property Development Limited Indanes as NRF2 activators
UA127872C2 (uk) 2018-12-05 2024-01-31 Скохія Фарма, Інк. Макроциклічна сполука та її застосування
WO2021002473A1 (ja) 2019-07-03 2021-01-07 千寿製薬株式会社 Nrf2活性化化合物
AU2021226994A1 (en) 2020-02-28 2022-09-08 Les Laboratoires Servier New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202253A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2018109647A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
JP2021535118A (ja) 2018-08-20 2021-12-16 ヤンセン ファーマシューティカ エヌ.ベー. KEAP1−Nrf2タンパク質−タンパク質相互作用の阻害剤
JP2022520442A (ja) 2019-02-15 2022-03-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Nrf2活性剤としてのヒドロキシピリドキシアゼピン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEIGHTMAN, Tom D. et al.,Structure-activity and structure-conformation relationships of aryl propionic acid inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction,Journal of Medicinal Chemistry,2019年04月11日,vol.62,p.4683-4702

Also Published As

Publication number Publication date
AU2020283361B2 (en) 2025-11-27
CN114174289A (zh) 2022-03-11
US20220259223A1 (en) 2022-08-18
US12559504B2 (en) 2026-02-24
CA3142295A1 (en) 2020-12-03
WO2020241853A1 (ja) 2020-12-03
ES3047102T3 (en) 2025-12-03
EP3978073A4 (en) 2023-07-12
MX2021014680A (es) 2022-04-06
BR112021023927A2 (pt) 2022-02-08
CN114174289B (zh) 2025-03-07
KR20220016124A (ko) 2022-02-08
EP3978073B1 (en) 2025-10-15
KR102978107B1 (ko) 2026-06-16
EP3978073A1 (en) 2022-04-06
JPWO2020241853A1 (cg-RX-API-DMAC7.html) 2020-12-03
EP3978073C0 (en) 2025-10-15
AU2020283361A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
CN114174289B (zh) 苯并三唑衍生物
AU2018311198B2 (en) Selective inhibitors of NLRP3 inflammasome
EP4356969B1 (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
US6861530B2 (en) Piperidine derivatives
KR20190026827A (ko) 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
CA3172478A1 (en) Bcl-2 inhibitor
TW201311692A (zh) 三唑並嘧啶類衍生物、其製備方法及其在醫藥上的應用
EP3816163A1 (en) Cell necrosis inhibitor, preparation method therefor and use thereof
CA2860187A1 (en) Cyclic amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase and uses thereof
CN116806219A (zh) 羟基杂环烷-氨甲酰基衍生物
US20250034156A1 (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza
WO2024078392A1 (en) Phosphoramidate compounds and uses thereof
US12297193B2 (en) PTPN2/PTP1B degrader and therapeutic method thereof
RU2840112C2 (ru) Производные бензотриазола
JP7750584B2 (ja) ピリミジン-環化トリアゾール誘導体及び血小板凝集の阻害におけるそれらの使用
HK40119293A (en) Fused tricyclic pyridazinone compounds and prodrugs thereof useful to treat orthomyxovirus infections
HK40110231A (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
CN122029151A (zh) 他汀类衍生物及其使用方法
HK40109763A (en) Pyrimidine-annulated triazole derivatives and their use in platelet aggregation inhibition
HK40055239B (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
HK40042824A (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
HK40042824B (en) 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
HK1180673A1 (zh) 新型异羟肟酸衍生物
HK1180673B (en) Novel hydroxamic acid derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240701

R150 Certificate of patent or registration of utility model

Ref document number: 7524899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150